Nuvation Bio Inc. Share-based Payment Arrangement, Expense
Nuvation Bio Inc. (NUVB) reported Share-based Payment Arrangement, Expense of $10.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- Nuvation Bio Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $10.46M, a 13.06% decline year-over-year.
- Nuvation Bio Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $9.03M, a 15.01% increase year-over-year.
- Nuvation Bio Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $7.99M, a 21.60% decline year-over-year.
- Nuvation Bio Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $8.02M, a 7.29% increase year-over-year.
- Nuvation Bio Inc. share-based payment arrangement, expense for fiscal 2025 was $35.89M, a 11.21% increase from fiscal 2024.
- Nuvation Bio Inc. share-based payment arrangement, expense for fiscal 2024 was $32.27M, a 65.40% increase from fiscal 2023.
- Nuvation Bio Inc. share-based payment arrangement, expense for fiscal 2023 was $19.51M, a 19.77% increase from fiscal 2022.
- Nuvation Bio Inc. share-based payment arrangement, expense for fiscal 2022 was $16.29M, a 75.79% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.46M 10-Q · filed 2026-08-06 | $19.49M 10-Q · filed 2026-08-06 | $27.48M derived: sum of 3 quarters · filed 2026-08-06 | $35.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.03M 10-Q · filed 2026-05-04 | $17.02M derived: sum of 2 quarters · filed 2026-05-04 | $25.04M derived: sum of 3 quarters · filed 2026-05-04 | $37.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $16.01M derived: sum of 2 quarters · filed 2026-03-02 | $28.04M derived: sum of 3 quarters · filed 2026-08-06 | $35.89M 10-K · filed 2026-03-02 |
| 2025-09-30 | $8.02M 10-Q · filed 2025-11-03 | $20.05M derived: sum of 2 quarters · filed 2026-08-06 | $27.91M 10-Q · filed 2025-11-03 | $38.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $12.03M 10-Q · filed 2026-08-06 | $19.89M 10-Q · filed 2026-08-06 | $30.07M derived: sum of 3 quarters · filed 2026-08-06 | $37.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.85M 10-Q · filed 2026-05-04 | $18.04M derived: sum of 2 quarters · filed 2026-05-04 | $25.52M derived: sum of 3 quarters · filed 2026-05-04 | $35.09M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $10.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $17.66M derived: sum of 2 quarters · filed 2026-03-02 | $27.23M derived: sum of 3 quarters · filed 2026-03-02 | $32.27M 10-K · filed 2026-03-02 |
| 2024-09-30 | $7.48M 10-Q · filed 2025-11-03 | $17.05M derived: sum of 2 quarters · filed 2025-11-03 | $22.09M 10-Q · filed 2025-11-03 | $25.81M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $9.57M 10-Q · filed 2025-08-07 | $14.61M 10-Q · filed 2025-08-07 | $18.33M derived: sum of 3 quarters · filed 2025-08-07 | $23.76M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.04M 10-Q · filed 2025-05-07 | $8.76M derived: sum of 2 quarters · filed 2025-05-07 | $14.19M derived: sum of 3 quarters · filed 2025-05-07 | $19.72M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $9.15M derived: sum of 2 quarters · filed 2025-03-06 | $14.68M derived: sum of 3 quarters · filed 2025-03-06 | $19.51M 10-K · filed 2025-03-06 |
| 2023-09-30 | $5.43M 10-Q · filed 2024-11-06 | $10.95M derived: sum of 2 quarters · filed 2024-11-06 | $15.79M 10-Q · filed 2024-11-06 | $20.78M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $5.52M 10-Q · filed 2024-08-05 | $10.36M 10-Q · filed 2024-08-05 | $15.35M derived: sum of 3 quarters · filed 2024-08-05 | $18.29M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $4.84M 10-Q · filed 2024-05-14 | $9.82M derived: sum of 2 quarters · filed 2024-05-14 | $12.77M derived: sum of 3 quarters · filed 2024-05-14 | $17.55M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.93M derived: sum of 2 quarters · filed 2024-02-29 | $12.71M derived: sum of 3 quarters · filed 2024-02-29 | $16.29M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.94M 10-Q · filed 2023-11-02 | $7.73M derived: sum of 2 quarters · filed 2023-11-02 | $11.30M 10-Q · filed 2023-11-02 | $14.10M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $4.79M 10-Q · filed 2023-08-03 | $8.36M 10-Q · filed 2023-08-03 | $11.16M derived: sum of 3 quarters · filed 2023-08-03 | $13.91M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $3.58M 10-Q · filed 2023-05-04 | $6.38M derived: sum of 2 quarters · filed 2023-05-04 | $9.13M derived: sum of 3 quarters · filed 2023-05-04 | $11.28M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $5.55M derived: sum of 2 quarters · filed 2023-03-15 | $7.70M derived: sum of 3 quarters · filed 2023-03-15 | $9.27M 10-K · filed 2023-03-15 |
| 2021-09-30 | $2.75M 10-Q · filed 2022-11-03 | $4.90M derived: sum of 2 quarters · filed 2022-11-03 | $6.47M 10-Q · filed 2022-11-03 | $7.59M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $2.15M 10-Q · filed 2022-08-04 | $3.72M 10-Q · filed 2022-08-04 | $4.84M derived: sum of 3 quarters · filed 2022-08-04 | $5.19M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.57M 10-Q · filed 2022-05-09 | $2.69M derived: sum of 2 quarters · filed 2022-05-09 | $3.04M derived: sum of 3 quarters · filed 2022-05-09 | $3.43M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.47M derived: sum of 2 quarters · filed 2022-02-28 | $1.86M derived: sum of 3 quarters · filed 2022-02-28 | $2.20M 10-K · filed 2022-02-28 |
| 2020-09-30 | $348.00K 10-Q · filed 2021-11-10 | $737.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.08M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $389.00K 10-Q · filed 2021-08-12 | $729.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $340.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |